Oceana Calls on Coca-Cola Europacific Partners to Safeguard and Grow Reuse in Advance of Proposed Acquisition of Coca-Cola Philippines
Nearly 50% of everything Coca-Cola sells is in reusable packaging in the Philippines. Oceana calls on CCEP to commit to reuse to protect the oceans from single-use plastic pollution.
WASHINGTON, D.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Oceana, the largest international advocacy organization focused solely on ocean conservation, formally requested that Coca-Cola Europacific Partners (CCEP) commit to increase, and not decrease, the share of refillable bottles sold in the Philippines in light of the company’s proposed acquisition of Coca-Cola Beverages Philippines with Aboitiz Equity Ventures Inc. (AEV). In a letter to the companies’ leaders, Oceana expressed concern for CCEP’s lack of a specific commitment and goal for growing the share of products it sells in reusable containers.
“We believe this commitment is critical for protecting the health of the oceans,” wrote Oceana’s Senior Vice President Matt Littlejohn and Oceana’s Vice President in the Philippines Atty. Gloria Estenzo Ramos in the letter. “This is especially important for the Philippines as the archipelagic nature of the country makes it particularly vulnerable to marine pollution, affecting both its rich biodiversity and its population relying on these waters for sustenance.”
In the letter, Oceana calls for:
- CCEP to commit to increase the sale and use of refillable bottles in the Philippines.
- CCEP to leverage the knowledge and capability gained from the Philippines to increase the sale and use of refillables in Indonesia, where CCEP is also the main distributor of Coca-Cola products.
- CCEP to pledge to increase its share of refillables by at least 10 percentage points in line with the Coca-Cola Company’s recent pledge to reach 25% reusable packaging by 2030 (up from a 14% share today).
Refillable bottles get reused as many as 25-50 times, depending on what material they are made of (plastic or glass). This means that each refillable bottle has the potential to replace 24-49 single-use plastic bottles.
The Philippines is currently one of the largest markets for refillable bottles on the planet. Refillable bottles currently account for nearly 50% of all Coca-Cola products sold in the Philippines, but only 15% of CCEP’s packaging units in Europe were returnable and refillable in 2022. The company has not committed to increase its share of refillable packaging globally or in key ocean countries, like Indonesia which was acquired by CCEP in 2020.
Single-use plastics cause immense harm to marine life and the broader ecosystem. An estimated 33 billion pounds of plastic enter the ocean every year and, if nothing changes, the amount of plastic entering the ocean is projected to triple by 2040. A report by Oceana found that increasing refillables by 10 percentage points in all coastal countries in place of single-use plastic could keep as many as 7.6 billion plastic bottles out of the ocean every year.
“We genuinely hope CCEP will further reduce its plastic dependence and transition to reusable packaging. Please know that we stand ready to both commend progress and rally concerned stakeholders for this cause,” Littlejohn and Ramos added.
The full letter is available here.
Oceana is the largest international advocacy organization dedicated solely to ocean conservation. Oceana is rebuilding abundant and biodiverse oceans by winning science-based policies in countries that control one-quarter of the world’s wild fish catch. With more than 275 victories that stop overfishing, habitat destruction, oil and plastic pollution, and the killing of threatened species like turtles, whales, and sharks, Oceana’s campaigns are delivering results. A restored ocean means that 1 billion people can enjoy a healthy seafood meal every day, forever. Together, we can save the oceans and help feed the world. Visit Oceana.org to learn more.
Contact: Anna Baxter, email@example.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote
Monument Reports Fourth Quarter and Fiscal 2023 Results29.9.2023 21:26:28 CEST | Press release
Gross Revenue of US$12.39 Million and Cash Cost of US$917/Oz for Gold Sulphide Production and US$1,622/Oz for Gold Oxide Production VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2023. All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results). Cathy Zhai, the President and CEO commented, “Fiscal 2023 was a milestone year for the Company with the gold sulphide project completed, and the flotation plant was put into production at the Selinsing Gold Mine in Malaysia. The commercial production has also been reached in August 2023 subsequent to the year end. It again demonstrates Monument has been able to deliver what’s been promised and now we are ready for the next corporate move.” Fiscal Year 2023 Highlights: Construction of the Selinsing sulphide flotation pla
Nokia Corporation: Repurchase of own shares on 29.09.202329.9.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 29 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 29.09.2023 Espoo, Finland – On 29 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL319,5513.57CEUX58,3773.57AQEU11,0113.57TQEX4,7613.57Total393,7003.57 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar
EPH European Property Holdings PLC announces Unaudited Interim Results for the Six Months to 30 June 2023 and appointment of Management Committee Members29.9.2023 19:00:00 CEST | Press release
29 September 2023, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS FIRST HALF YEAR OF 2023 With an established portfolio of high-quality properties in prime locations in Europe occupied by tenants with strong credit ratings, combined with professional asset management, EPH European Property Holdings PLC (“EPH” or the “Company”) has demon-strated operational stability in the first six months of 2023, despite the ongoing market environment challenges. As a result, EPH not only achieved almost full occupancy throughout its European portfolio, it also increased rental income.The sale of the Company’s Russian portfolio was concluded in April 2023, following the Extraordinary General Meeting (held on 1 November 2022) at which the shareholders of EPH authorised the Board of Directors to sell EPH Group’s entire Russian property portfolio by way of a management buyout. Upon disposal of the Russian segment in the first half of 2023, the Company reclassified the
Oxurion Publishes First Half 2023 Results29.9.2023 19:00:00 CEST | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US –September 29, 2023 – 7.00PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel